Stem cells: The impatient advocate.

The article discusses the contribution of Bob Klein as chairman of the California Institute for Regenerative Medicine (CIRM). It mentions the legacy that he left after his resignation on December 17, 2010 including six new facilities, 700 scientific papers and 1.15 billion U.S. dollars in grants. It also notes his advocacy on the promotion of human embryonic stem-cell research in the U.S. to seek an effective treatment for diabetes.